Capula Management’s Ginkgo Bioworks DNA Stock Holding History

Capula Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,454	Closed	-$503K	–	526
2023 Q1	$503K	Buy	+9,454	New	+$599K	0.01%	434

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Capula Management's DNA Position: Q2 2023 in Review

Capula Management sold out of Ginkgo Bioworks (DNA) in Q2 2023, closing a stake of 9,454 shares — an estimated $503K sold.

Capula Management first reported a position in DNA in Q1 2023 and held it in 1 quarter. The position peaked at $503K in Q1 2023. 315 funds tracked by Wall St. Rank hold DNA as of Q2 2023.

Capula Management reported no remaining Ginkgo Bioworks position as of Q2 2023 after selling out during the quarter.
Capula Management sold 9,454 Ginkgo Bioworks shares in Q2 2023, an estimated $503K.
Capula Management first reported a position in Ginkgo Bioworks in Q1 2023 and held it in 1 quarter.
Capula Management's Ginkgo Bioworks position peaked at $503K in Q1 2023.
315 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2023.

Based on Capula Management's 13F filing for Q2 2023, filed 14 Aug 2023.